Details of the Drug Combination

General Information of Drug Combination (ID: DCMT3F2)

• Drug Combination Name: Elacestrant + Triptorelin
• Indication: Breast Cancer; Status: Phase 2 [1]
• Component Drugs:
  Elacestrant (DM8RLJ5): N.A.
  Triptorelin (DMTK4LS): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Elacestrant

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[2]

Elacestrant Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Estrogen receptor (ESR)	TTZAYWL	ESR1_HUMAN	Modulator	[6]

Indication(s) of Triptorelin

Disease Entry	ICD 11	Status	REF
Infertility	GB04	Approved	[3]
Solid tumour/cancer	2A00-2F9Z	Approved	[4]
Prostate cancer	2C82.0	Phase 4	[5]

Triptorelin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Gonadotropin-releasing hormone receptor (GNRHR)	TT8R70G	GNRHR_HUMAN	Modulator	[7]

References

• [1] ClinicalTrials.gov (NCT05982093) Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
• [2] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217639.
• [3] Triptorelin FDA Label
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1177).
• [5] ClinicalTrials.gov (NCT00633347) Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation. U.S. National Institutes of Health.
• [6] RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct;26(9):948-56.
• [7] Regulation of GnRH I receptor gene expression by the GnRH agonist triptorelin, estradiol, and progesterone in the gonadotroph-derived cell line alphaT3-1. Endocrine. 2006 Aug;30(1):139-44.